{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:43:22Z","timestamp":1793133802011,"version":"4.5.0"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Azacitidine, a hypomethylating agent, has caused a paradigm shift in the outcomes of patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) who are not eligible for stem cell transplantation, particularly in combination with BCL2 and IDH inhibitors. Azacitidine and Azacitidine-based combinations have been widely considered a safe low-intensity therapy when compared to traditional conventional treatments. The development of lung toxicity from azacitidine is not a well-characterized adverse event. However, if it happens, it can be fatal, especially if not recognized and treated promptly. In this review, we aim to familiarize the reader with the presentation of azacitidine-induced lung injury, provide our suggested approach to management based on our experience and the current understanding of its mechanism, and review the literature of 20 case reports available on this topic.<\/jats:p>","DOI":"10.3389\/fonc.2024.1345492","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T05:01:00Z","timestamp":1707454860000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Azacitidine induced lung injury: report and contemporary discussion on diagnosis and management"],"prefix":"10.3389","volume":"14","author":[{"given":"Ruah","family":"Alyamany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Alnughmush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malak","family":"Almutlaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Alyamany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour","family":"Alfayez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.25.5.765.63579","article-title":"Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome","volume":"25","author":"Adams","year":"2005","journal-title":"Pharmacotherapy"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/0300060517698331","article-title":"Azacitidine-induced acute lung injury in a patient with therapy-related myelodysplastic syndrome","volume":"45","author":"Makita","year":"2017","journal-title":"J Int Med Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-016-0803-0","article-title":"Azacitidine-induced cryptogenic organizing pneumonia: A case report and review of the literature","volume":"10","author":"Alnimer","year":"2016","journal-title":"J Med Case Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.14740\/jh227w","article-title":"Rare respiratory and neurologic adverse reactions to azacitidine in the treatment of myelodysplastic syndrome of patients treated at the ottawa hospital","volume":"4","author":"Ahrari","year":"2015","journal-title":"J Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.51.8167","article-title":"Azacitidine-induced pneumonitis in a patient with myelodysplastic syndrome: First case report in Japan","volume":"51","author":"Hayashi","year":"2012","journal-title":"Internal Med"},{"key":"B6","unstructured":"SekhriA\n            PalaniswamyC\n            KurmayagariK\n            KalraA\n            SelvarajDR\n          Interstitial Lung Disease Associated with Azacitidine Use: A Case Report"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.04094","article-title":"DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia","volume":"80","author":"R\u00fcter","year":"2004","journal-title":"Int J Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-163246","article-title":"Aberrant DNA methylation is a dominant mechanism in MDS progression to AML","volume":"113","author":"Jiang","year":"2009","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bbrc.2014.08.140","article-title":"Compendium of aberrant DNA methylation and histone modifications in cancer","volume":"455","author":"Hattori","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-236349","article-title":"Azacitidine-induced pneumonitis and literature review","volume":"13","author":"Nguyen","year":"2020","journal-title":"BMJ Case Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22570","article-title":"Myelodysplastic syndromes","volume":"109","author":"Ma","year":"2007","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-81947-6_15","article-title":"Inhibition of DNA methylation by 5-azacytidine","volume-title":"Modified Nucleosides and Cancer","author":"Jones","year":"1983"},{"key":"B13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0092-8674(83)90327-6","article-title":"On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs","volume":"33","author":"Santi","year":"1983","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1042\/bj3070087","article-title":"The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor","volume":"307","author":"Gabbara","year":"1995","journal-title":"Biochem J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1634\/theoncologist.6-suppl_5-8","article-title":"Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS)","volume":"6","author":"Silverman","year":"2001","journal-title":"Oncologist"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/21.3.461","article-title":"DNA methylation: past, present and future directions","volume":"21","author":"Robertson","year":"2000","journal-title":"Carcinogenesis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"New Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3494-3","article-title":"Autopsy findings in patients with acute myeloid leukemia and non-Hodgkin lymphoma in the modern era: a focus on lung pathology and acute respiratory failure","volume":"98","author":"Van de Louw","year":"2019","journal-title":"Ann Hematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1053\/j.seminoncol.2005.11.005","article-title":"Pulmonary toxicity of chemotherapy","volume":"33","author":"Meadors","year":"2006","journal-title":"Semin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.07034","article-title":"Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy","volume":"86","author":"Oki","year":"2007","journal-title":"Int J Hematol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/ajh.24253","article-title":"Myelodysplastic syndromes: Contemporary review and how we treat","volume":"91","author":"Gangat","year":"2016","journal-title":"Am J Hematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12185-011-0987-4","article-title":"Combination strategies in myelodysplastic syndromes","volume":"95","author":"Ornstein","year":"2012","journal-title":"Int J Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1 -mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"New Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp040385","article-title":"Azacitidine: A novel agent for myelodysplastic syndromes","volume":"62","author":"Sullivan","year":"2005","journal-title":"Am J Health-System Pharmacy."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-85-2-237","article-title":"5-azacytidine","volume":"85","author":"Von Hoff","year":"1976","journal-title":"Ann Intern Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.01338","article-title":"Eosinophilic pneumonia associated with azacitidine in a patient with myelodysplastic syndrome","volume":"57","author":"Nair","year":"2012","journal-title":"Respir Care"},{"key":"B29","first-page":"451","article-title":"The inhibition of DNA(Cytosine-5) methylases by 5-azacytidine: the effect of azacytosine-containing DNA","volume":"20","author":"Friedman","year":"1981","journal-title":"Mol Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s40800-017-0047-y","article-title":"How to diagnose early 5-azacytidine-induced pneumonitis: A case report","volume":"4","author":"Misra","year":"2017","journal-title":"Drug Saf Case Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.010611","article-title":"5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis","volume":"95","author":"Gurion","year":"2010","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205699","article-title":"5-Azacytidine and 5-aza-2\u2032-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy","volume":"21","author":"Christman","year":"2002","journal-title":"Oncogene"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(02)00028-0","article-title":"Treatment of myelodysplastic syndromes with 5-azacytidine","volume":"26","author":"Gryn","year":"2002","journal-title":"Leuk Res"},{"key":"B35","volume-title":"Vidaza (azacitidine) Package Insert. Boulder, CO","year":"2004"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients","volume":"279","author":"Lazarou","year":"1998","journal-title":"JAMA"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26758","article-title":"Azacitidine-induced pneumonitis in a patient with acute myeloid leukemia and hyperleukocytosis","volume":"14","author":"Litvin","year":"2022","journal-title":"Cureus"},{"key":"B38","unstructured":"VerriereB\n            FerreiraV\n            DenisE\n          Azacitidine-induced Interstitial Pneumonitis2015"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.4346","article-title":"Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421 8921, and 9221 by the Cancer and Leukemia Group B","volume":"24","author":"Silverman","year":"2006","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-3-176","article-title":"FDA drug approval summary: azacitidine (5-azacytidine, vidazaTM) for injectable suspension","volume":"10","author":"Kaminskas","year":"2005","journal-title":"Oncologist"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S3143","article-title":"Safety and efficacy of azacitidine in myelodysplastic syndromes","volume":"221","author":"Vigil","year":"2010","journal-title":"Drug Des Devel Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.09.024","article-title":"Interstitial pneumonitis\u2014An important differential diagnosis for pulmonary sepsis in haematology patients","volume":"36","author":"Pillai","year":"2012","journal-title":"Leuk Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/357461","article-title":"Pulmonary complications of azanucleoside therapy in patients with myelodysplastic syndrome and acute myelogenous leukemia","volume":"2015","author":"Molina","year":"2015","journal-title":"Case Rep Hematol"},{"key":"B44","article-title":"Case report A 64-year-old Male with Fever and Persistent Lung Infiltrate","volume-title":"Respir Care","author":"Vasu","year":"2009"},{"key":"B45","doi-asserted-by":"publisher","first-page":"210094","DOI":"10.1183\/16000617.0094-2021","article-title":"Cryptogenic organising pneumonia: current understanding of an enigmatic lung disease","volume":"30","author":"Raghu","year":"2021","journal-title":"Eur Respir Review."},{"key":"B46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12325-011-0024-2","article-title":"Azacitidine adverse effects in patients with myelodysplastic syndromes","volume":"28","author":"San Miguel Amigo","year":"2011","journal-title":"Adv Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000824","article-title":"Delayed onset of azacitidine-associated pneumotitis: A case report","volume":"26","author":"Oka","year":"2019","journal-title":"Am J Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official american thoracic society\/european respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.53.1971","article-title":"Azacitidine-associated acute interstitial pneumonitis","volume":"53","author":"Kuroda","year":"2014","journal-title":"Internal Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1046\/j.0767-3981.2003.00206.x","article-title":"Gemcitabine-induced severe pulmonary toxicity","volume":"18","author":"Barl\u00e9si","year":"2004","journal-title":"Fundam Clin Pharmacol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970715)80:2<286::AID-CNCR17>3.0.CO;2-Q","article-title":"Fatal pulmonary toxicity resulting from treatment with gemcitabine","volume":"80","author":"Pavlakis","year":"1997","journal-title":"Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-011-1013-1","article-title":"Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer","volume":"137","author":"Umemura","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"B53","article-title":"Severe interstitial pneumonitis related to Gemcitabine","volume":"19","author":"Sabria-Trias","year":"2002","journal-title":"Rev Mal Respir"},{"key":"B54","first-page":"91","article-title":"Respiratory function and alveolar biological changes under the effect of CDP-choline in pulmonary interstitial pathology: pulmonary fibrosis and sarcoidosis","volume":"41","author":"Pacheco","year":"1985","journal-title":"Rev Pneumol Clin"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.26443\/mjm.v21i1.983","article-title":"Schwartzman K. A case of organizing pneumonia following azacitidine treatment for myelodysplastic syndrome","volume":"21","author":"Hutchinson","year":"2023","journal-title":"McGill J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.pulmoe.2022.06.010","article-title":"Azacytidine-induced pneumonitis in acute myeloid leukaemia","volume":"29","author":"Cabral","year":"2023","journal-title":"Pulmonology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.12.013","article-title":"Hypomethylating therapy and autoimmunity in MDS: An enigmatic relationship","volume":"36","author":"Kotsianidis","year":"2012","journal-title":"Leuk Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0272-5231(03)00141-2","article-title":"Drug-induced eosinophilic lung disease","volume":"25","author":"Allen","year":"2004","journal-title":"Clin Chest Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.153.4.8616578","article-title":"Cytokine production at the site of disease in chronic eosinophilic pneumonitis","volume":"153","author":"Kita","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00204","article-title":"Proteomic analysis reveals autophagy as pro-survival pathway elicited by long-term exposure with 5-azacitidine in high-risk myelodysplasia","volume":"8","author":"Romano","year":"2017","journal-title":"Front Pharmacol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1369\/0022155420932103","article-title":"Identification of autophagy-related proteins in lungs from hypersensitivity pneumonitis patients","volume":"68","author":"Cabrera","year":"2020","journal-title":"J Histochem Cytochemistry."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.75","article-title":"Immunopathogenesis of granulomas in chronic autoinflammatory diseases","volume":"5","author":"Timmermans","year":"2016","journal-title":"Clin Transl Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2009.01.004","article-title":"Sarcoidosis as a benign cause of lymphadenopathy in cancer patients","volume":"197","author":"Hunt","year":"2009","journal-title":"Am J Surgery."},{"key":"B65","article-title":"Brief azacytidine step allows the conversion of suspension human fibroblasts into neural progenitor-like cells citation","volume-title":"Cell J","author":"Mirakhori","year":"2015"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201201-0077OC","article-title":"Altered DNA methylation profile in idiopathic pulmonary fibrosis","volume":"186","author":"Sanders","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(84)90942-2","article-title":"Demethylation of the type I procollagen genes in transformed fibroblasts treated with 5-azacytidine","volume":"124","author":"Parker","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1378\/chest.121.5.1478","article-title":"The role of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in cryptogenic organizing pneumonia","volume":"121","author":"Choi","year":"2002","journal-title":"Chest"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/PL00007654","article-title":"Apoptotic activity is increased in the newly formed fibromyxoid connective tissue in bronchiolitis obliterans organizing pneumonia","volume":"177","author":"Lappi-Blanco","year":"1999","journal-title":"Lung"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.12.1759","article-title":"Azacitidine-associated hyperthermia and interstitial pneumonitis in a patient with myelodysplastic syndrome","volume":"27","author":"Hueser","year":"2007","journal-title":"Pharmacotherapy"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.155.1.9001319","article-title":"Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis","volume":"155","author":"Baumgartner","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/142.2.374","article-title":"Sequential virus infections, bacterial superinfections, and fibrogenesis","volume":"142","author":"Jakab","year":"1990","journal-title":"Am Rev Respir Disease."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.97.10071433","article-title":"Viruses and idiopathic pulmonary fibrosis","volume":"10","author":"Egan","year":"1997","journal-title":"Eur Respir J"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.3.9701093","article-title":"Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis","volume":"157","author":"Hubbard","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/152.4.307","article-title":"Occupational and environmental risk factors for idiopathic pulmonary fibrosis: A multicenter case-control study","volume":"152","author":"Baumgartner","year":"2000","journal-title":"Am J Epidemiol."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.158.6.9804105","article-title":"Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis","volume":"158","author":"Tobin","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0910538","article-title":"The paradox of the neutrophil'The paradox of the neutrophs role in tissue injury","volume":"89","author":"Segel","year":"2011","journal-title":"J Leukoc Biol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403270","article-title":"Incidence and prognostic value of respiratory events in acute leukemia","volume":"18","author":"Chaoui","year":"2004","journal-title":"Leukemia"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001920","article-title":"American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults","volume":"4","author":"Sekeres","year":"2020","journal-title":"Blood Adv"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00013505","article-title":"Cryptogenic organising pneumonia","volume":"28","author":"Cordier","year":"2006","journal-title":"Eur Respir J"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e10630","article-title":"Organizing pneumonia secondary to amiodarone treatment","volume":"8","author":"Carvalho","year":"2022","journal-title":"Heliyon"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.56.2.161","article-title":"BOOP associated with nitrofurantoin","volume":"56","author":"Fawcett","year":"2001","journal-title":"Thorax"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.03.036","article-title":"Development of interstitial lung disease after initiation of apixaban anticoagulation therapy","volume":"25","author":"Tomari","year":"2016","journal-title":"J Stroke Cerebrovascular Diseases."},{"key":"B84","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0272-5231(03)00123-0","article-title":"Chemotherapy-induced lung disease","volume":"25","author":"Limper","year":"2004","journal-title":"Clin Chest Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.04.1847","article-title":"Drug-induced eosinophilic pneumonia: high-resolution CT findings in 14 patients","volume":"186","author":"Souza","year":"2006","journal-title":"Am J Roentgenology."},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1148\/radiographics.20.5.g00se081245","article-title":"Pulmonary drug toxicity: radiologic and pathologic manifestations","volume":"20","author":"Rossi","year":"2000","journal-title":"RadioGraphics"},{"key":"B87","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/CPM.0b013e3181d2a1d6","article-title":"Eosinophilic lung disease","volume":"17","author":"Li","year":"2010","journal-title":"Clin Pulm Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.2.ats3-00","article-title":"Idiopathic pulmonary fibrosis: diagnosis and treatment","volume":"161","author":"King","year":"2000","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1345492\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T05:01:06Z","timestamp":1707454866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1345492\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":88,"alternative-id":["10.3389\/fonc.2024.1345492"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1345492","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,9]]},"article-number":"1345492"}}